№ lp_1_2_31916
File format: docx
Character count: 2259
File size: 958 KB
This document provides the Standard Operating Procedure for NHS Trusts to access ctDNA testing kits for ESR1 ctDNA testing, outlining the process for obtaining, using, and returning the kits to NW GLH for testing.
Year:
2023
Region / City:
Manchester
Topic:
ctDNA Testing, ESR1 Pathway
Document Type:
Standard Operating Procedure
Organization:
North West Genomic Laboratory Hub (NWGLH)
Author:
Not specified
Target Audience:
NHS Trusts, Clinical Teams
Action Period:
Ongoing
Approval Date:
Not specified
Revision Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
North West NHS GMS region
Topic:
ctDNA testing for NSCLC and breast cancer
Document Type:
Notification
Organization:
NHS England
Author:
Genomics Unit
Target Audience:
NHS Trusts
Period of Action:
2025/26 financial year
Approval Date:
7 November 2025
Date of Changes:
N/A
Context:
Notification regarding the continuation and expansion of ctDNA testing for lung and breast cancer in the North West NHS region for the 2025/26 financial year.
Year:
2026
Region / City:
Not specified
Topic:
Cancer genomics, epigenetics, prostate cancer
Document type:
Supplementary material
Institution:
Not specified
Authors:
Chennan Li et al.
Target audience:
Researchers in oncology and molecular biology
Sample type:
Plasma and buffy coat
Methods:
ctDNA sequencing, 5mC/5hmC methylomics, clonal reconstruction
Timepoints:
Baseline, restaging, progression, off-study
Genes analyzed:
AR, BRCA2, erythroid markers, platelet/megakaryocyte markers, globins
Data included:
Sequencing metrics, methylation percentages, gene-level events, survival analysis
Associated figures:
8 supplementary figures, 2 supplementary tables
Statistical analyses:
Spearman correlation, Kruskal-Wallis test, Mann-Whitney U test, Kaplan-Meier survival estimates, log-rank test
Year:
2021–2024
Authors:
Cabalag, Hofste, Morimoto, Ng, Ococks, Kelly, van den Ende, Veschoor, Wang, Yue
Number of patients:
20–111 per study
Type of document:
Supplementary table
Data points:
ctDNA detection at baseline, after NAT, and after surgery
Study population:
Patients undergoing ctDNA tests
Measurement type:
Evaluable blood samples and ctDNA presence
Context:
Scientific supplementary table presenting the distribution of patients with evaluable blood samples and ctDNA detection results across multiple studies in clinical research
Year:
2026
Region / City:
London, United Kingdom; Urbana, Illinois, USA; New York City, USA; Glasgow, United Kingdom
Topic:
Breast cancer, ESR1 mutations, drug resistance
Document Type:
Research article
Institution:
The Institute of Cancer Research; University of Illinois at Urbana-Champaign; Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College; The Royal Marsden Hospital
Authors:
Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J Cutts, Heena Shah, Laura Moretti, Lucy S Kilburn, Hannah Johnson, Iain R Macpherson, Alistair Ring, Judith M Bliss, Yingwei Hou, Weiyi Toy, John A Katzenellenbogen, Sarat Chandarlapaty, Nicholas C Turner
Keywords:
Fulvestrant, acquired resistance, ESR1 F404, breast cancer, PIK3CA, TP53, ESR1 D538G, ESR1 E380Q, ESR1 Y537N
Methods:
Patient cohort analysis, progression-free survival assessment, CRISPR gene editing, RNA sequencing, clonogenic assays
Target Audience:
Oncologists, cancer researchers, molecular biologists
Supplementary Data:
Figures 1–9, mutation incidence, gene expression, drug response curves
Clinical Focus:
Acquired resistance to fulvestrant in ESR1 mutant breast cancer models
Document section:
Supplementary table S4
Subject:
ESR1 G2014A gene polymorphism and osteoporosis risk
Academic field:
Genetic epidemiology
Type of document:
Supplementary scientific table
Study design:
Meta-analysis of case–control studies
Population characteristics:
Female participants with specified menopausal status
Countries represented:
Mexico; Thailand
Geographic regions:
South America; East Asia
Ethnicity groups:
Mixed; Asian
Control source:
Population-based (PB); Hospital-based (HB)
Genetic focus:
ESR1 G2014A polymorphism
Variables reported:
Genotype distribution; allele distribution; minor allele frequency; Hardy–Weinberg equilibrium p-value
Sample information:
Cases and controls with genotype counts (A/A, A/G, G/G)
Total samples reported:
640; 228; 358; 352; 66
Authors cited:
Gómez R et al.; Ongphiphadhanakul B et al.; Wajanavisit et al.
Years of referenced studies:
2001; 2003; 2005; 2007; 2015
Year:
2022
Region / City:
Liverpool
Subject:
Quality Management, Genomics Laboratory
Document Type:
Quality Manual
Organization / Institution:
North West Genomics Laboratory Hub – Liverpool Site
Author:
Unknown
Target Audience:
Laboratory management, staff, and inspection/accreditation bodies
Period of Validity:
Ongoing
Approval Date:
August 1, 2019
Modification Date:
August 2021
The document is a Quality Manual for the North West Genomics Laboratory Hub – Liverpool Site, outlining the Quality Management System and referencing ISO 15189:
2022 standards for laboratory accreditation and operations.
Year:
2020
Region / City:
International
Subject:
Business
Document Type:
Delivery Plan
Organization:
Pearson
Author:
Pearson
Target Audience:
Tutors and educators delivering BTEC International Level 3 qualifications
Period of validity:
From April 2020
Approval Date:
N/A
Modification Date:
N/A
Year:
2023
Note:
Region / City
Subject:
Information Technology
Document Type:
Scheme of Work
Qualification:
Cambridge Technicals in Health and Social Care
Unit:
Unit 3 – Health, Safety and Security in Health and Social Care
Guided Learning Hours:
60 GLH
Learning Outcomes:
LO1 Understand potential hazards in health, social care and childcare environments; LO2 Understand how legislation, policies and procedures promote health, safety and security in health, social care and childcare environments
Topics Covered:
Types of hazards; Types of settings; Potential impacts of hazards; Harm and abuse; Legislation; Safeguarding; Influences of legislation; Implementation of policies and procedures
Settings Referenced:
Health environments; Care environments; Childcare environments; Public environments; Transport
Organisations Referenced:
National Health Service (NHS); National Society for the Prevention of Cruelty to Children (NSPCC); Health and Safety Executive (HSE)
Legislation Referenced:
Health and Safety at Work Act 1974; Control of Substances Hazardous to Health (COSHH) Regulations; RIDDOR; Civil Contingencies Act; Food Safety legislation
Intended Users:
Teachers and centres delivering the qualification
Assessment Context:
Classroom-based teaching, group work, research activities, case study analysis
Resource Type:
Outline scheme of work and delivery guidance
Geographical Context:
United Kingdom
Year:
2023
Region / City:
United Kingdom
Topic:
Genomic Testing, Tumour Referral
Document Type:
Referral Form
Organization / Institution:
NW Genomic Laboratory Hub
Author:
Not specified
Target Audience:
Clinicians, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified